Boosting ADCC and CDC activity by Fc engineering and evaluation of antibody effector functions. (Q48012057)

7 February 2018

title

Boosting ADCC and CDC activity by Fc engineering and evaluation of antibody effector functions. (English)

1 reference

7 February 2018

1 reference

Christian Kellner

1

1 reference

7 February 2018

Stefanie Derer

series ordinal

2

1 reference

7 February 2018

Thomas Valerius

series ordinal

3

1 reference

7 February 2018

Matthias Peipp

series ordinal

4

1 reference

7 February 2018

publication date

9 July 2013

1 reference

7 February 2018

published in

Methods

1 reference

7 February 2018

volume

65

1 reference

7 February 2018

issue

1

1 reference

7 February 2018

page(s)

105-113

1 reference

7 February 2018

Potent antibody therapeutics by design

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Monoclonal antibodies for cancer immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Antibody-based immunotherapy of cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Marketed therapeutic antibodies compendium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Addition of fresh frozen plasma as a source of complement to rituximab in advanced chronic lymphocytic leukaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Enhancing the action of rituximab by adding fresh frozen plasma for the treatment of fludarabine refractory chronic lymphocytic leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Complement activation determines the therapeutic activity of rituximab in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Divergent immunoglobulin g subclass activity through selective Fc receptor binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Complement function in mAb-mediated cancer immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

C5a anaphylatoxin is a major regulator of activating versus inhibitory FcgammaRs in immune complex-induced lung disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcγ receptor engagement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Monocyte subsets responsible for immunoglobulin G-dependent effector functions in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Molecular engineering and design of therapeutic antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Optimization of Fc-mediated effector functions of monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Engineered antibody Fc variants with enhanced effector function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

The Fc-engineered CD19 antibody MOR208 (XmAb5574) induces natural killer cell-mediated lysis of acute lymphoblastic leukemia cells from pediatric and adult patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

The impact of Fc engineering on an anti-CD19 antibody: increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

The C1q receptor site on human immunoglobulin G.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Engineered antibodies with increased activity to recruit complement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Structure of the murine unglycosylated IgG1 Fc fragment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Glycosylation as a strategy to improve antibody-based therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Terminal sugars of Fc glycans influence antibody effector functions of IgGs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Lectin-resistant CHO glycosylation mutants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

The joys of HexNAc. The synthesis and function of N- and O-glycan branches

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Influence of variable N-glycosylation on the cytolytic potential of chimeric CD19 antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Rapid production of recombinant human IgG With improved ADCC effector function in a transient expression system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Unique carbohydrate-carbohydrate interactions are required for high affinity binding between Fc RIII and antibodies lacking core fucose

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Nonfucosylated rituximab potentiates human neutrophil phagocytosis through its high binding for FcgammaRIIIb and MHC class II expression on the phagocytotic neutrophils

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Phase I Pharmacokinetic and Pharmacodynamic Dose-Escalation Study of RG7160 (GA201), the First Glycoengineered Monoclonal Antibody Against the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

CD20 antibodies: type II to tango?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Engineering host cell lines to reduce terminal sialylation of secreted antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

IgG-Fc glycoengineering in non-mammalian expression hosts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Optimization of humanized IgGs in glycoengineered Pichia pastoris.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Chemoenzymatic glycoengineering of intact IgG antibodies for gain of functions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Enhanced binding affinity for FcgammaRIIIa of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Aglycosylated IgG variants expressed in bacteria that selectively bind FcgammaRI potentiate tumor cell killing by monocyte-dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Engineering Hydrophobic Protein–Carbohydrate Interactions to Fine-Tune Monoclonal Antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Assessing Fc glycan heterogeneity of therapeutic recombinant monoclonal antibodies using NP-HPLC.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Mechanism of action of therapeutic monoclonal antibodies: promises and pitfalls of in vitro and in vivo assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Tumor cell killing mechanisms of epidermal growth factor receptor (EGFR) antibodies are not affected by lung cancer-associated EGFR kinase mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

High throughput screening for antibody induced complement-dependent cytotoxicity in early antibody discovery using homogeneous macroconfocal fluorescence imaging.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Complement dependent cytotoxicity (CDC) activity of a humanized anti Lewis-Y antibody: FACS-based assay versus the 'classical' radioactive method -- qualification, comparison and application of the FACS-based approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

A novel multiparametric flow cytometry-based cytotoxicity assay simultaneously immunophenotypes effector cells: comparisons to a 4 h 51Cr-release assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Evaluation of antibody-dependent cell cytotoxicity using lactate dehydrogenase (LDH) measurement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Compensation of endogenous IgG mediated inhibition of antibody-dependent cellular cytotoxicity by glyco-engineering of therapeutic antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

A complement-dependent cytotoxicity-enhancing anti-CD20 antibody mediating potent antitumor activity in the humanized NOD/Shi-scid, IL-2Rγ(null) mouse lymphoma model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Fcgamma receptors: old friends and new family members

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Crosstalk between human IgG isotypes and murine effector cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Mouse model recapitulating human Fcγ receptor structural and functional diversity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Humanized mice: are we there yet?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

CD28 superagonists: what makes the difference in humans?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Comparison of novel methods for predicting the risk of pro-inflammatory clinical infusion reactions during monoclonal antibody therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Improved in vitro methods to predict the in vivo toxicity in man of therapeutic monoclonal antibodies including TGN1412

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Molecular engineering to improve antibodies' anti-lymphoma activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Production of non-fucosylated antibodies by co-expression of heterologous GDP-6-deoxy-D-lyxo-4-hexulose reductase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Engineering Chinese hamster ovary cells to maximize effector function of produced antibodies using FUT8 siRNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

CHO-gmt5, a novel CHO glycosylation mutant for producing afucosylated and asialylated recombinant antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Structural Basis for Fc RIIa Recognition of Human IgG and Formation of Inflammatory Signaling Complexes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

The crystal structure of the globular head of complement protein C1q provides a basis for its versatile recognition properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.06.036

10.1016/J.YMETH.2013.06.036

7 January 2021

Identifiers

DOI

1 reference

7 February 2018

release_dyp7qjpmwveizbuxgnypcl52ky

Fatcat ID

0 references

PubMed ID

23851282

1 reference

7 February 2018